BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Frampton AE, Krell J, Jamieson NB, Gall TM, Giovannetti E, Funel N, Mato Prado M, Krell D, Habib NA, Castellano L. microRNAs with prognostic significance in pancreatic ductal adenocarcinoma: A meta-analysis. Eur J Cancer. 2015;51:1389-1404. [PMID: 26002251 DOI: 10.1016/j.ejca.2015.04.006] [Cited by in Crossref: 64] [Cited by in F6Publishing: 62] [Article Influence: 9.1] [Reference Citation Analysis]
Number Citing Articles
1 You L, Wang J, Zhang F, Zhang J, Tao H, Zheng X, Hu Y. Potential four‑miRNA signature associated with T stage and prognosis of patients with pancreatic ductal adenocarcinoma identified by co‑expression analysis. Mol Med Rep 2019;19:441-51. [PMID: 30483731 DOI: 10.3892/mmr.2018.9663] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
2 Zhang W, Chen J, He G, Xu W, He G. Impact of mirna-21 on survival prognosis in patients with pancreatic cancer: A protocol for systematic review and meta-analysis. Medicine (Baltimore) 2020;99:e22045. [PMID: 32871962 DOI: 10.1097/MD.0000000000022045] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
3 Visani M, Acquaviva G, Fiorino S, Bacchi Reggiani ML, Masetti M, Franceschi E, Fornelli A, Jovine E, Fabbri C, Brandes AA, Tallini G, Pession A, de Biase D. Contribution of microRNA analysis to characterisation of pancreatic lesions: a review. J Clin Pathol 2015;68:859-69. [DOI: 10.1136/jclinpath-2015-203246] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
4 Zhou X, Huang Z, Xu L, Zhu M, Zhang L, Zhang H, Wang X, Li H, Zhu W, Shu Y, Liu P. A panel of 13-miRNA signature as a potential biomarker for predicting survival in pancreatic cancer. Oncotarget 2016;7:69616-24. [PMID: 27626307 DOI: 10.18632/oncotarget.11903] [Cited by in Crossref: 35] [Cited by in F6Publishing: 39] [Article Influence: 8.8] [Reference Citation Analysis]
5 Liu K, Wang L, Sun E. Prognostic value of miR-221 in human malignancy: evidence from 3041 subjects. BMC Cancer 2019;19:867. [PMID: 31470827 DOI: 10.1186/s12885-019-6079-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
6 Khan K, Cunningham D, Peckitt C, Barton S, Tait D, Hawkins M, Watkins D, Starling N, Rao S, Begum R, Thomas J, Oates J, Guzzardo V, Fassan M, Braconi C, Chau I. miR-21 expression and clinical outcome in locally advanced pancreatic cancer: exploratory analysis of the pancreatic cancer Erbitux, radiotherapy and UFT (PERU) trial. Oncotarget 2016;7:12672-81. [PMID: 26862857 DOI: 10.18632/oncotarget.7208] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 5.6] [Reference Citation Analysis]
7 Wei DM, Jiang MT, Lin P, Yang H, Dang YW, Yu Q, Liao DY, Luo DZ, Chen G. Potential ceRNA networks involved in autophagy suppression of pancreatic cancer caused by chloroquine diphosphate: A study based on differentially‑expressed circRNAs, lncRNAs, miRNAs and mRNAs. Int J Oncol 2019;54:600-26. [PMID: 30570107 DOI: 10.3892/ijo.2018.4660] [Cited by in F6Publishing: 20] [Reference Citation Analysis]
8 Erb U, Zhao K, Wang Z, Xiao L, Zöller M. Murine and human pancreatic tumor exosome recovery in mouse serum: Diagnostic and prognostic potential and target cell delivery. Cancer Lett 2017;403:1-12. [PMID: 28619525 DOI: 10.1016/j.canlet.2017.06.005] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
9 Zhang QA, Yang XH, Chen D, Yan X, Jing FC, Liu HQ, Zhang R. miR-34 increases in vitro PANC-1 cell sensitivity to gemcitabine via targeting Slug/PUMA. Cancer Biomark 2018;21:755-62. [PMID: 29355113 DOI: 10.3233/CBM-170289] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
10 Loosen SH, Neumann UP, Trautwein C, Roderburg C, Luedde T. Current and future biomarkers for pancreatic adenocarcinoma. Tumour Biol 2017;39:101042831769223. [DOI: 10.1177/1010428317692231] [Cited by in Crossref: 39] [Cited by in F6Publishing: 44] [Article Influence: 7.8] [Reference Citation Analysis]
11 Supadmanaba IGP, Mantini G, Randazzo O, Capula M, Muller IB, Cascioferro S, Diana P, Peters GJ, Giovannetti E. Interrelationship between miRNA and splicing factors in pancreatic ductal adenocarcinoma. Epigenetics 2021;:1-24. [PMID: 34057028 DOI: 10.1080/15592294.2021.1916697] [Reference Citation Analysis]
12 Yan T, Ke Y, Chen Y, Xu C, Yu C, Li Y. Serological characteristics of autoimmune pancreatitis and its differential diagnosis from pancreatic cancer by using a combination of carbohydrate antigen 19-9, globulin, eosinophils and hemoglobin. PLoS One. 2017;12:e0174735. [PMID: 28369140 DOI: 10.1371/journal.pone.0174735] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
13 Ren L, Yu Y. The role of miRNAs in the diagnosis, chemoresistance, and prognosis of pancreatic ductal adenocarcinoma. Ther Clin Risk Manag 2018;14:179-87. [PMID: 29416345 DOI: 10.2147/TCRM.S154226] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
14 Sekita-Hatakeyama Y, Nishikawa T, Takeuchi M, Morita K, Takeda M, Hatakeyama K, Nakai T, Uchiyama T, Itami H, Fujii T, Mitoro A, Sho M, Ohbayashi C. K-ras mutation analysis of residual liquid-based cytology specimens from endoscopic ultrasound-guided fine needle aspiration improves cell block diagnosis of pancreatic ductal adenocarcinoma. PLoS One 2018;13:e0193692. [PMID: 29494669 DOI: 10.1371/journal.pone.0193692] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
15 Abreu TR, Biscaia M, Gonçalves N, Fonseca NA, Moreira JN. In Vitro and In Vivo Tumor Models for the Evaluation of Anticancer Nanoparticles. Adv Exp Med Biol 2021;1295:271-99. [PMID: 33543464 DOI: 10.1007/978-3-030-58174-9_12] [Reference Citation Analysis]
16 Cancer Genome Atlas Research Network. Cancer Genome Atlas Research Network. Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma. Cancer Cell. 2017;32:185-203.e13. [PMID: 28810144 DOI: 10.1016/j.ccell.2017.07.007] [Cited by in Crossref: 700] [Cited by in F6Publishing: 595] [Article Influence: 140.0] [Reference Citation Analysis]
17 Le Large TYS, Bijlsma MF, Kazemier G, van Laarhoven HWM, Giovannetti E, Jimenez CR. Key biological processes driving metastatic spread of pancreatic cancer as identified by multi-omics studies. Semin Cancer Biol. 2017;44:153-169. [PMID: 28366542 DOI: 10.1016/j.semcancer.2017.03.008] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 5.6] [Reference Citation Analysis]
18 Rajabpour A, Rajaei F, Teimoori-toolabi L. Molecular alterations contributing to pancreatic cancer chemoresistance. Pancreatology 2017;17:310-20. [DOI: 10.1016/j.pan.2016.12.013] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 4.8] [Reference Citation Analysis]
19 Škrha P, Hořínek A, Pazourková E, Hajer J, Frič P, Škrha J, Anděl M. Serum microRNA-196 and microRNA-200 in pancreatic ductal adenocarcinoma of patients with diabetes mellitus. Pancreatology 2016;16:839-43. [PMID: 27267055 DOI: 10.1016/j.pan.2016.05.005] [Cited by in F6Publishing: 10] [Reference Citation Analysis]
20 Frampton AE, Krell J, Prado MM, Gall TM, Abbassi-Ghadi N, Del Vecchio Blanco G, Funel N, Giovannetti E, Castellano L, Basyouny M, Habib NA, Kaltsidis H, Vlavianos P, Stebbing J, Jiao LR. Prospective validation of microRNA signatures for detecting pancreatic malignant transformation in endoscopic-ultrasound guided fine-needle aspiration biopsies. Oncotarget. 2016;7:28556-28569. [PMID: 27086919 DOI: 10.18632/oncotarget.8699] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
21 Xie Y, Ma X, Chen L, Li H, Gu L, Gao Y, Zhang Y, Li X, Fan Y, Chen J, Zhang X. MicroRNAs with prognostic significance in bladder cancer: a systematic review and meta-analysis. Sci Rep 2017;7:5619. [PMID: 28717125 DOI: 10.1038/s41598-017-05801-3] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 4.2] [Reference Citation Analysis]
22 Hackeng WM, Hruban RH, Offerhaus GJ, Brosens LA. Surgical and molecular pathology of pancreatic neoplasms. Diagn Pathol 2016;11:47. [PMID: 27267993 DOI: 10.1186/s13000-016-0497-z] [Cited by in Crossref: 58] [Cited by in F6Publishing: 51] [Article Influence: 9.7] [Reference Citation Analysis]
23 Goto T, Fujiya M, Konishi H, Sasajima J, Fujibayashi S, Hayashi A, Utsumi T, Sato H, Iwama T, Ijiri M, Sakatani A, Tanaka K, Nomura Y, Ueno N, Kashima S, Moriichi K, Mizukami Y, Kohgo Y, Okumura T. An elevated expression of serum exosomal microRNA-191, - 21, -451a of pancreatic neoplasm is considered to be efficient diagnostic marker. BMC Cancer. 2018;18:116. [PMID: 29385987 DOI: 10.1186/s12885-018-4006-5] [Cited by in Crossref: 78] [Cited by in F6Publishing: 83] [Article Influence: 19.5] [Reference Citation Analysis]
24 Sabarimurugan S, Madurantakam Royam M, Das A, Das S, K M G, Jayaraj R. Systematic Review and Meta-analysis of the Prognostic Significance of miRNAs in Melanoma Patients. Mol Diagn Ther 2018;22:653-69. [PMID: 30259393 DOI: 10.1007/s40291-018-0357-5] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 7.3] [Reference Citation Analysis]
25 Kanno S, Nosho K, Ishigami K, Yamamoto I, Koide H, Kurihara H, Mitsuhashi K, Shitani M, Motoya M, Sasaki S, Tanuma T, Maguchi H, Hasegawa T, Kimura Y, Takemasa I, Shinomura Y, Nakase H. MicroRNA-196b is an independent prognostic biomarker in patients with pancreatic cancer. Carcinogenesis 2017;38:425-31. [DOI: 10.1093/carcin/bgx013] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 5.2] [Reference Citation Analysis]
26 Kanat O, Ertas H. Shattering the castle walls: Anti-stromal therapy for pancreatic cancer. World J Gastrointest Oncol 2018; 10(8): 202-210 [PMID: 30147846 DOI: 10.4251/wjgo.v10.i8.202] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
27 Hasan S, Jacob R, Manne U, Paluri R. Advances in pancreatic cancer biomarkers. Oncol Rev 2019;13:410. [PMID: 31044028 DOI: 10.4081/oncol.2019.410] [Cited by in Crossref: 39] [Cited by in F6Publishing: 36] [Article Influence: 13.0] [Reference Citation Analysis]
28 Xu P, Xia T, Ling Y, Chen B. MiRNAs with prognostic significance in multiple myeloma: A systemic review and meta-analysis. Medicine (Baltimore) 2019;98:e16711. [PMID: 31415363 DOI: 10.1097/MD.0000000000016711] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
29 Stroese AJ, Ullerich H, Koehler G, Raetzel V, Senninger N, Dhayat SA. Circulating microRNA-99 family as liquid biopsy marker in pancreatic adenocarcinoma. J Cancer Res Clin Oncol 2018;144:2377-90. [PMID: 30225540 DOI: 10.1007/s00432-018-2749-7] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
30 Sharma GG, Okada Y, Von Hoff D, Goel A. Non-coding RNA biomarkers in pancreatic ductal adenocarcinoma. Semin Cancer Biol 2020:S1044-579X(20)30204-2. [PMID: 33049362 DOI: 10.1016/j.semcancer.2020.10.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
31 Garajová I, Balsano R, Tommasi C, Giovannetti E. Noncoding Rnas Emerging as Novel Biomarkers in Pancreatic Cancer. CPD 2019;24:4601-4. [DOI: 10.2174/1381612825666190119125804] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
32 Gao Z, Jiang W, Zhang S, Li P. The State of the Art on Blood MicroRNAs in Pancreatic Ductal Adenocarcinoma. Anal Cell Pathol (Amst) 2019;2019:9419072. [PMID: 31583198 DOI: 10.1155/2019/9419072] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
33 Wald P, Liu XS, Pettit C, Dillhoff M, Manilchuk A, Schmidt C, Wuthrick E, Chen W, Williams TM. Prognostic value of microRNA expression levels in pancreatic adenocarcinoma: a review of the literature. Oncotarget 2017;8:73345-61. [PMID: 29069873 DOI: 10.18632/oncotarget.20277] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 3.2] [Reference Citation Analysis]
34 Li J, Wu H, Li W, Yin L, Guo S, Xu X, Ouyang Y, Zhao Z, Liu S, Tian Y, Tian Z, Ju J, Ni B, Wang H. Downregulated miR-506 expression facilitates pancreatic cancer progression and chemoresistance via SPHK1/Akt/NF-κB signaling. Oncogene 2016;35:5501-14. [PMID: 27065335 DOI: 10.1038/onc.2016.90] [Cited by in Crossref: 92] [Cited by in F6Publishing: 97] [Article Influence: 15.3] [Reference Citation Analysis]
35 Uddin MH, Al-Hallak MN, Philip PA, Mohammad RM, Viola N, Wagner KU, Azmi AS. Exosomal microRNA in Pancreatic Cancer Diagnosis, Prognosis, and Treatment: From Bench to Bedside. Cancers (Basel) 2021;13:2777. [PMID: 34204940 DOI: 10.3390/cancers13112777] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
36 Tesfaye AA, Azmi AS, Philip PA. miRNA and Gene Expression in Pancreatic Ductal Adenocarcinoma. Am J Pathol 2019;189:58-70. [PMID: 30558723 DOI: 10.1016/j.ajpath.2018.10.005] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 6.0] [Reference Citation Analysis]
37 Diab M, Muqbil I, Mohammad RM, Azmi AS, Philip PA. The Role of microRNAs in the Diagnosis and Treatment of Pancreatic Adenocarcinoma. J Clin Med 2016;5:E59. [PMID: 27322337 DOI: 10.3390/jcm5060059] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 3.2] [Reference Citation Analysis]
38 Sun X, Zhou X, Zhang Y, Zhu X, Liu H. Systematic Review and Meta-Analysis of Diagnostic Accuracy of miRNAs in Patients with Pancreatic Cancer. Dis Markers. 2018;2018:6292396. [PMID: 29887920 DOI: 10.1155/2018/6292396] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 3.5] [Reference Citation Analysis]
39 Dou D, Yang S, Lin Y, Zhang J. An eight-miRNA signature expression-based risk scoring system for prediction of survival in pancreatic adenocarcinoma. Cancer Biomark 2018;23:79-93. [PMID: 29991127 DOI: 10.3233/CBM-181420] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
40 Zhu SK. Role of precision medicine in pancreatic cancer. Shijie Huaren Xiaohua Zazhi 2016; 24(36): 4752-4758 [DOI: 10.11569/wcjd.v24.i36.4752] [Reference Citation Analysis]
41 Xu YF, Xu X, Bhandari K, Gin A, Rao CV, Morris KT, Hannafon BN, Ding WQ. Isolation of extra-cellular vesicles in the context of pancreatic adenocarcinomas: Addition of one stringent filtration step improves recovery of specific microRNAs. PLoS One 2021;16:e0259563. [PMID: 34784377 DOI: 10.1371/journal.pone.0259563] [Reference Citation Analysis]
42 Previdi MC, Carotenuto P, Zito D, Pandolfo R, Braconi C. Noncoding RNAs as novel biomarkers in pancreatic cancer: what do we know? Future Oncol 2017;13:443-53. [PMID: 27841659 DOI: 10.2217/fon-2016-0253] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 5.7] [Reference Citation Analysis]
43 Barnett RE, Conklin DJ, Ryan L, Keskey RC, Ramjee V, Sepulveda EA, Srivastava S, Bhatnagar A, Cheadle WG. Anti-inflammatory effects of miR-21 in the macrophage response to peritonitis. J Leukoc Biol 2016;99:361-71. [PMID: 26382295 DOI: 10.1189/jlb.4A1014-489R] [Cited by in Crossref: 51] [Cited by in F6Publishing: 34] [Article Influence: 7.3] [Reference Citation Analysis]
44 Wolfe AR, Wald P, Webb A, Sebastian N, Walston S, Robb R, Chen W, Vedaie M, Dillhoff M, Frankel WL, Kwon W, Jang JY, Williams TM. A microRNA-based signature predicts local-regional failure and overall survival after pancreatic cancer resection. Oncotarget 2020;11:913-23. [PMID: 32206188 DOI: 10.18632/oncotarget.27496] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
45 Le Large TY, Meijer LL, Prado MM, Kazemier G, Frampton AE, Giovannetti E. Circulating microRNAs as diagnostic biomarkers for pancreatic cancer. Expert Rev Mol Diagn 2015;15:1525-9. [PMID: 26567751 DOI: 10.1586/14737159.2015.1112273] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
46 Kapodistrias N, Mavridis K, Batistatou A, Gogou P, Karavasilis V, Sainis I, Briasoulis E, Scorilas A. Assessing the clinical value of microRNAs in formalin-fixed paraffin-embedded liposarcoma tissues: Overexpressed miR-155 is an indicator of poor prognosis. Oncotarget. 2017;8:6896-6913. [PMID: 28036291 DOI: 10.18632/oncotarget.14320] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
47 Xu YF, Hannafon BN, Zhao YD, Postier RG, Ding WQ. Plasma exosome miR-196a and miR-1246 are potential indicators of localized pancreatic cancer. Oncotarget. 2017;8:77028-77040. [PMID: 29100367 DOI: 10.18632/oncotarget.20332] [Cited by in Crossref: 66] [Cited by in F6Publishing: 73] [Article Influence: 13.2] [Reference Citation Analysis]
48 Eid M, Karousi P, Kunovský L, Tuček Š, Brančíková D, Kala Z, Slabý O, Mayer J, Kontos CK, Trna J. The Role of Circulating MicroRNAs in Patients with Early-Stage Pancreatic Adenocarcinoma. Biomedicines 2021;9:1468. [PMID: 34680585 DOI: 10.3390/biomedicines9101468] [Reference Citation Analysis]
49 Erb U, Zöller M. Progress and potential of exosome analysis for early pancreatic cancer detection. Expert Rev Mol Diagn 2016;16:757-67. [PMID: 27206554 DOI: 10.1080/14737159.2016.1187563] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
50 Lü L, Mao X, Shi P, He B, Xu K, Zhang S, Wang J. MicroRNAs in the prognosis of triple-negative breast cancer: A systematic review and meta-analysis. Medicine (Baltimore) 2017;96:e7085. [PMID: 28562579 DOI: 10.1097/MD.0000000000007085] [Cited by in Crossref: 43] [Cited by in F6Publishing: 34] [Article Influence: 8.6] [Reference Citation Analysis]
51 Rajamani D, Bhasin MK. Identification of key regulators of pancreatic cancer progression through multidimensional systems-level analysis. Genome Med 2016;8:38. [PMID: 27137215 DOI: 10.1186/s13073-016-0282-3] [Cited by in Crossref: 30] [Cited by in F6Publishing: 32] [Article Influence: 5.0] [Reference Citation Analysis]
52 Mikamori M, Yamada D, Eguchi H, Hasegawa S, Kishimoto T, Tomimaru Y, Asaoka T, Noda T, Wada H, Kawamoto K, Gotoh K, Takeda Y, Tanemura M, Mori M, Doki Y. MicroRNA-155 Controls Exosome Synthesis and Promotes Gemcitabine Resistance in Pancreatic Ductal Adenocarcinoma. Sci Rep 2017;7:42339. [PMID: 28198398 DOI: 10.1038/srep42339] [Cited by in Crossref: 103] [Cited by in F6Publishing: 113] [Article Influence: 20.6] [Reference Citation Analysis]
53 Kandimalla R, Shimura T, Mallik S, Sonohara F, Tsai S, Evans DB, Kim SC, Baba H, Kodera Y, Von Hoff D, Chen X, Goel A. Identification of Serum miRNA Signature and Establishment of a Nomogram for Risk Stratification in Patients With Pancreatic Ductal Adenocarcinoma. Ann Surg 2020. [PMID: 32398486 DOI: 10.1097/SLA.0000000000003945] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
54 Morani AC, Hanafy AK, Ramani NS, Katabathina VS, Yedururi S, Dasyam AK, Prasad SR. Hereditary and Sporadic Pancreatic Ductal Adenocarcinoma: Current Update on Genetics and Imaging. Radiol Imaging Cancer 2020;2:e190020. [PMID: 33778702 DOI: 10.1148/rycan.2020190020] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
55 Kim Y, Lee S, Jang JY, Lee S, Park T. Identifying miRNA-mRNA Integration Set Associated With Survival Time. Front Genet 2021;12:634922. [PMID: 34267778 DOI: 10.3389/fgene.2021.634922] [Reference Citation Analysis]
56 Xiong G, Feng M, Yang G, Zheng S, Song X, Cao Z, You L, Zheng L, Hu Y, Zhang T, Zhao Y. The underlying mechanisms of non-coding RNAs in the chemoresistance of pancreatic cancer. Cancer Lett. 2017;397:94-102. [PMID: 28254409 DOI: 10.1016/j.canlet.2017.02.020] [Cited by in Crossref: 32] [Cited by in F6Publishing: 39] [Article Influence: 6.4] [Reference Citation Analysis]
57 Mentis AA, Dardiotis E, Romas NA, Papavassiliou AG. PIWI family proteins as prognostic markers in cancer: a systematic review and meta-analysis. Cell Mol Life Sci 2020;77:2289-314. [PMID: 31814070 DOI: 10.1007/s00018-019-03403-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
58 Robinson SM, Fan L, White SA, Charnley RM, Mann J. The role of exosomes in the pathogenesis of pancreatic ductal adenocarcinoma. Int J Biochem Cell Biol. 2016;75:131-139. [PMID: 27017975 DOI: 10.1016/j.biocel.2016.03.009] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
59 Liang L, Wei DM, Li JJ, Luo DZ, Chen G, Dang YW, Cai XY. Prognostic microRNAs and their potential molecular mechanism in pancreatic cancer: A study based on The Cancer Genome Atlas and bioinformatics investigation. Mol Med Rep 2018;17:939-51. [PMID: 29115476 DOI: 10.3892/mmr.2017.7945] [Cited by in Crossref: 8] [Cited by in F6Publishing: 20] [Article Influence: 1.6] [Reference Citation Analysis]
60 Benesova L, Halkova T, Bunganic B, Belsanova B, Zavoral M, Traboulsi E, Minarik M. Comparison of Native Aspirates and Cytological Smears Obtained by EUS-Guided Biopsies for Effective DNA/RNA Marker Testing in Pancreatic Cancer. Pathol Oncol Res. 2018;. [PMID: 30361898 DOI: 10.1007/s12253-018-0490-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
61 Baines A, Martin P, Rorie C. Current and Emerging Targeting Strategies for Treatment of Pancreatic Cancer. Molecular and Cellular Changes in the Cancer Cell. Elsevier; 2016. pp. 277-320. [DOI: 10.1016/bs.pmbts.2016.09.006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
62 Rapado-González Ó, Majem B, Muinelo-Romay L, López-López R, Suarez-Cunqueiro MM. Cancer Salivary Biomarkers for Tumours Distant to the Oral Cavity. Int J Mol Sci 2016;17:E1531. [PMID: 27626410 DOI: 10.3390/ijms17091531] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
63 Wang L, Zhang N, Wang Z, Ai DM, Cao ZY, Pan HP. Pseudogene PTENP1 Functions as a Competing Endogenous RNA (ceRNA) to Regulate PTEN Expression by Sponging miR-499-5p. Biochemistry (Mosc) 2016;81:739-47. [PMID: 27449620 DOI: 10.1134/S0006297916070105] [Cited by in Crossref: 17] [Cited by in F6Publishing: 10] [Article Influence: 3.4] [Reference Citation Analysis]
64 Quiñonero F, Mesas C, Doello K, Cabeza L, Perazzoli G, Jimenez-Luna C, Rama AR, Melguizo C, Prados J. The challenge of drug resistance in pancreatic ductal adenocarcinoma: a current overview. Cancer Biol Med 2019;16:688-99. [PMID: 31908888 DOI: 10.20892/j.issn.2095-3941.2019.0252] [Cited by in F6Publishing: 15] [Reference Citation Analysis]